AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Currently Amended) <u>AnFour</u> isolated <u>or syntheticisoformes of peptide comprising a member selected from the group consisting of:, with anti-hypertensive properties, named as TsHpt-I (Tityus serrulatus Hypotensin-I), TsHpt-II (Tityus serrulatus Hypotensin-II), TsHpt-III (Tityus serrulatus Hypotensin-III) and TsHpt-IV (Tityus serrulatus Hypotensin-IV), and refereed as listed sequences SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3 and SEQ ID NO: 4.</u>
- 2. (Currently Amended) An isolated or synthetic peptide expressed in a venom of a scorpion, wherein the peptide comprises at least two features selected from the group consisting of Other peptides from scorpions (presently taxonomic classification as follows: Eukariota; Metazoa; Arthropoda, Chelicerata; Arachnida; Scorpiones) belonging to the same pharmacologically active and structurally peptide family, characterized by two or more following features: i) lack of Cystein residues and, therefore, no lack of internal disulfide bridges; ii) a molecular signature at the a C-terminal ending or portion, described as: Xaa-Pro-Pro andor Xaa-Pro-Pro-Ala, where Xaa is any amino acid residue; iii) pairs of amino acid residues such as Pro-Pro, Lys Glu, Lys Asp, Arg Glu, Arg Asp, Ile Ile, Ile Leu, Leu Leu, Leu-Ile, which effective to form a protective shield against amino-, endo- and carboxi- proteinases enzymes; and iv) Hypotensive effects using "in vivo" tests (bioassays)-in vertebrates. This family of scorpion peptides will be refereed hereinbelow as Scorpion Hypotensive Peptides (SHptP).

National Stage of PCT/BR03/00073 Attorney Docket No. B1204/20002 Preliminary Amendment Dated December 7, 2004

- 3. (Currently Amended) An isolated or synthetic peptide Synthetic peptides comprising a complete, partial or modified sequences of a member selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3 and SEQ ID NO: 4, wherein the peptide is an anti-hypertensive agentelaim 1-and/or molecular signatures of claim 2.
- 4. (Currently Amended) A nucleic acid molecule encoding the that codify for peptides of claim 1-and/or peptide family of claim 2.
- 5. (Currently Amended) <u>The Isolated and purified</u> peptides of claim 1, <u>and/or claim 2</u> wherein <u>the peptides are is produced</u> by recombinant techniques using <u>any virusa viral</u> system, any bacterial system, any fungal system, <u>or any other prokaryotic systems</u>, <u>or eukariotic other</u> eukaryotic systems or <u>a combination thereof</u>.
- 6. (Currently Amended) A method for producing any administrable pharmaceutical composition comprising the complete, partial or modified amino acid sequences peptide of claim 1 and claim 2.
- 7. (Currently Amended) A method for producing any a genetically modified virus, bacteria, fungi, plant or any other recombinant techniques using any virus system, any bacterial system, any fungal system or any other prokaryotic or eukarioticeukaryotic system or combination thereof, in order to use these organisms as excipient or vector for complete, partial or modified sequences of claim 1-and/or claim 2.
- 8. (Currently Amended) A pharmaceutical composition comprising an anti-hypertensive amount of the peptides of claim 1.

National Stage of PCT/BR03/00073 Attorney Docket No. B1204/20002 Preliminary Amendment Dated December 7, 2004

9. (Currently Amended) A method for labeling and/or chemically modifying <u>a peptides</u> of claim 1-and claim 2.